169 results about "Cocrystal" patented technology

A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.

The present invention relates to cocrystals including a scale-inhibiting compound, and methods of using the cocrystals for treating a subterranean formation. In various embodiments, the present invention provides a method of treating a subterranean formation including obtaining or providing a composition including cocrystals. Each cocrystal independently includes a scale-inhibiting compound and a secondary material. The method also includes placing the composition in a subterranean formation.

The present invention relates to energetic cocrystals, and to methods for using the same for treatment of a subterranean formation. In various embodiments, the present invention provides a method of treating a subterranean formation, the method including obtaining or providing a composition including energetic cocrystals. Each energetic cocrystal independently includes an energetic compound and a secondary material. The method also includes placing the composition in a subterranean formation.

The present disclosure relates to crystallizing a chemical substance(s) using ultrasound. Methods are provided for screening a chemical substance according to its solid forms by using ultrasound to generate new or unusual solid forms. Methods are also provided for crystallizing a chemical substance by novel techniques that include sonication. The present disclosure also relates to cocrystallization using ultrasound. Methods are provided for preparing cocrystals of an active agent and a guest by sonicating and crystallizing. Methods are also provided for screening a sample according to solid state phases (such as cocrystals and salts) and include generating a cocrystal from the sample using ultrasound.

The invention relates to a solid of tenofovir disoproxil. The solid is (1) a tenofovir disoproxil compound represented by a formula IV or (2) a tenofovir disoproxil cocrystal or salt represented by a formula V. The invention further relates to a preparation method for the solid of tenofovir disoproxil, a pharmaceutical composition containing the solid and application of the solid in preparation of drugs used for preventing and/or treating virus infection, especially hepatitis b virus (HBV) and/or human immunodeficiency virus (HIV) infection.

Process for preparing a cocrystal of an active substance and a cocrystal former, the process involving precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, in particular using a GAS, SAS, SEDS or SAS-EM process. The invention also provides a cocrystal prepared using such a process, and its use as a seed crystal in a subsequent process for precipitating a cocrystal of an active substance and a cocrystal former.

The invention belongs to the technical field of medicinal cocrystal, and particularly relates to a novel iloperidone medicinal cocrystal and a preparation method thereof. An N atom in a piperidine ring of iloperidone is used as a hydrogen bond donor, and an H atom on a carboxyl group in 3,5-pyridine dicarboxylic acid is used as a hydrogen bond receptor to form a hydrogen bond; an iloperidone molecule is combined with a 3,5-pyridine dicarboxylic acid molecule through the hydrogen bond to form a basic structural unit of the iloperidone medicinal cocrystal; and a space group of the medicinal cocrystal is a triclinic system. The preparation method of the iloperidone medicinal cocrystal is a reflux-room temperature volatilization method. The medicinal cocrystal prepared by using the preparation method disclosed by the invention has the characteristics of inheriting the conventional raw material medicament on treatment of schizophrenia; and the dissolubility, the stability and the bioavailability of the medicinal cocrystal are obviously improved.

The invention relates to a method for preparing pharmaceutical cocrystals through suspension crystallization. The method concretely comprises the following steps: firstly screening solid forms of active pharmaceutical ingredients API and cocrystal formation CCF in different solvents, preparing a CCF saturation solution together with a solvent which cannot generate solvate together with the API and CCF; feeding the prepared CCF saturation solution into a vessel type stirrer, feeding the solid API and CCF according to a certain solid load rate, and deciding the ratio of molar weight of the API and CCF according to the cocrysal chemical metrological ratio; and sampling to do XRD or DSC testing after fully stirring and mixing, so as to prove that the cocrystal solid phase is pure, performing vacuum filtration to the obtained solid, and washing and drying the CCF saturation solution to obtain a solid, namely a final cocrystal product. Compared with other methods, the method is low in energy consumption, less in used solvent, low in cost, simple in technology, easy to amplify, fast and easy to obtain, high in the purity of products, and suitable for industrial large-batch synthesized pharmaceutical cocrystals.

The invention discloses a preparation method of a hexanitrohexaazaisowurtzitane/p-benzoquinone cocrystal explosive. Firstly a saturated solution of hexanitrohexaazaisowurtzitane and a saturated solution of p-benzoquinone are prepared using a crystallization solvent, and then the solvent is allowed to evaporate through a constant-temperature incubator, followed by crystallization to prepare a hexanitrohexaazaisowurtzitane/p-benzoquinone cocrystal explosive. The invention has the benefits as follows: the crystal density of the hexanitrohexaazaisowurtzitane/p-benzoquinone cocrystal explosive is up to 1.737 g/cm3, the melting point of the cocrystal explosive is 132 DEG C and is greatly increased by 17 DEG C as compared with relatively-pure component PBQ, and the cocrystal decomposition temperature is lower than that of both CL-20 and BQ and 207 DEG C lower than that of PBQ. Therefore, by virtue of cocrystallization, the thermal decomposition behavior of the explosive can be obviously controlled, the high efficiency and desensitivity of cocrystallization of the explosive are achieved, the safety of the explosive is improved, and the explosive has a good application prospect in high-energy low-sensitivity ammunition.

A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.

The invention belongs to the technical field of pharmaceutical cocrystals and in particular relates to a novel iloperidone pharmaceutical cocrystal and a preparation method thereof. The pharmaceutical cocrystal is characterized in that iloperidone is taken as the active pharmaceutical ingredient, 3,5-dihydroxy-benzoic acid is taken as the former, and an iloperidone molecule, a 3,5-dihydroxy-benzoic acid molecule and a water molecule jointly form a basic structural unit of the iloperidone pharmaceutical cocrystal through hydrogen bonds and deposition. The pharmaceutical cocrystal is prepared by taking ethanol as the solvent and adopting the method of reflux-room temperature diffusion and volatilization. As the selected organic solvent has lower boiling point, crystals are prepared in the process of solvent volatilization after reflux and filtration. The prepared pharmaceutical cocrystal carries forward the characteristic of the traditional active pharmaceutical ingredients in treating schizophrenia and the dissolubility, stability and bioavailability of the pharmaceutical cocrystal are also obviously improved.

The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

The present disclosure relates inter alia to an organic cocrystal comprising at least three compounds A, B and C, and the method to prepare the said organic cocrystal, and organic electronic devices comprising the said organic cocrystal, and their application and use.

In a process for forming a nanoparticulate crystalline titanium phthalocyanine pigment composition, a titanium phthalocyanine pigment is contacted with substantially pure 1,1,2-trichloroethane (TCE) under conditions effective to convert the titanium phthalocyanine pigment to the nanoparticulate crystalline composition.

The invention discloses an olaparib and maleic acid cocrystal and a preparation method thereof. The molar ratio of olaparib to maleic acid in the cocrystal is 1:1, and an X-ray powder diffraction pattern of the cocrystal has characteristic peaks when the 2theta values are 5.1+/-0.2 degrees, 9.8+/-0.2 degrees, 13.7+/-0.2 degrees, 16.0+/-0.2 degrees, 17.7+/-0.2 degrees and 20.0+/-0.2 degrees. The cocrystal preparation method provided by the invention is simple in process, easy to control the crystallization process, good in reproducibility and suitable for industrial production. Compared with olaparib free alkali, the cocrystal has higher apparent solubility, and is beneficial to improving the oral absorption efficiency of olaparib.

2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms.

A 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal and its use as an opioid antagonist are disclosed. The invention also relates to a drug-in-adhesive transdermal patch containing the analgesic fentanyl, a mu opioid agonist, or an analog thereof and a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal, as an opioid antagonist. A transdermal patch of the invention is tamper-resistant and an abuse deterrent which protects against drug misuse or abuse. The invention also provides a method of treating pain, such as acute, chronic, or intermittent pain, by applying a drug-in-adhesive transdermal patch according to the invention to the skin of a patient in need thereof. Also disclosed is an improved transdermal patch for administering fentanyl or an analog thereof, or for administering a mu opioid agonist, the improvement wherein the transdermal patch contains a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal in an abuse limiting amount. The improved transdermal patch may be a drug-in-adhesive transdermal patch or a reservoir transdermal patch.

Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.

The invention particularly relates to an erythritol and sucralose cocrystal product and a cocrystallization method thereof. The technical proposal includes: firstly adding a sucralose aqueous solution to an erythritol melt liquid to prepare a clarified cocrystallization mother liquor; cooling the cocrystallization mother liquor to 100-120 DEG C, adding seed crystal and growing the crystal, and then cooling the crystal to obtain the erythritol and sucralose cocrystal. The invention has the characteristics of low production costs and short production cycles. The obtained erythritol and sucralose cocrystal has a single endothermic peak in a differential scanning calorimeter (DSC) analysis, a stable crystal structure and a smooth crystal surface, and the product is good in mouth dissolving sense, and has desired sweetness quality and excellent physical properties.

The present invention relates to a pigment composition composed of compounds of the formula (I), (II) and (III) with a novel crystal modification, to their preparation and to the use of this novel product as a pigment. For many applications of organic pigments, for example the coloring of metallic lacquers or the use thereof in color filters, a very high transparency is required. To produce color filters, for example, particularly fine pigments are used, in order to substantially rule out the particle scattering which leads to a lowering of the contrast ratio. The commercially available products, however, do not always meet all requirements of the art. More particularly, there was a need for improvement with regard to the transparency and the associated fineness of the pigment crystals, and also the color purity (chroma).